Hims & Hers Health (HIMS) opened Q1 2026 with revenue of US$608.1 million and a reported loss of US$92.1 million, equal to EPS of US$0.40 in the red. The company has seen quarterly revenue move from US$481.1 million in Q4 2024 to the US$544.8 million to US$617.8 million range through 2025. EPS shifted from US$0.12 to US$0.22 of profit in early 2025 before slipping back into a loss in the latest quarter. This sets up a results season in which investors will be weighing top line scale against pressure on margins.

See our full analysis for Hims & Hers Health.

With the headline numbers on the table, the next step is to set these results against the most widely held narratives around Hims & Hers and see which stories the latest margins support or challenge.

Losses Return After 2025 Profits

• After four straight quarters of profits in 2025, with net income between US$15.8 million and US$49.5 million, Q1 2026 swung back to a loss of US$92.1 million while revenue held at US$608.1 million.
• Bulls point to the longer trend of loss reduction over the past five years and forecast earnings growth of about 48.9% a year, yet the latest trailing twelve month line shows a small loss of US$13.2 million, which means:
  • Consensus narrative expects margins to improve over time, but Q1 2026 interrupts the recent run of quarterly profits from Q1 to Q4 2025.
  • Supporters of the bullish view will likely focus on whether the return to a loss is a temporary reset against the backdrop of roughly 13.1% trailing revenue growth.

On this set of numbers, bulls see a growth story that temporarily slipped back into the red but still argue that the bigger picture supports their case, which is laid out in more detail in the 🐂 Hims & Hers Health Bull Case.

Trailing Revenue Near US$2.4b, Profitability Still Fragile

• On a trailing twelve month basis, Hims & Hers booked US$2.37b of revenue with a small net loss of US$13.2 million, compared with quarterly revenue that has sat in the US$544.8 million to US$617.8 million range since early 2025.
• Bears argue that relying on high growth segments like weight loss and daily sexual health makes earnings vulnerable, and the shift from trailing profits of US$128.4 million a year ago to a small loss today gives that concern some footing:
  • The bearish narrative flags pressure on margins from marketing, international expansion and compliance costs, and the move from quarterly profits through 2025 to a loss in Q1 2026 aligns with that risk.
  • At the same time, revenue still tracks above the US market reference of 11.6% growth, so critics are watching whether future quarters keep translating that top line into sustainable profit.

Skeptics point to the fragile shift back into loss making and question how durable the growth story is, and their full argument is set out in 🐻 Hims & Hers Health Bear Case.

P/S of 2.4x Sits Between Peers and Sector

• Hims & Hers trades on a P/S of 2.4x, below the peer average of 4.3x but above the broader US healthcare industry at 1.2x, while the stock sits at US$25.03 against a DCF fair value of US$66.44 and an analyst price target anchor of US$26.61.
• Consensus narrative sees the stock as roughly fairly priced around analyst targets, yet the combination of a lower P/S than peers and a DCF fair value well above the current share price creates a tension:
  • Supporters of the balanced view can point to the company trading close to the US$26.61 analyst target while still being cheaper than peers on P/S, suggesting expectations are already building in both growth potential and execution risks.
  • On the other hand, the gap between US$25.03 and the US$66.44 DCF fair value in the data set implies that any slip in the path to profitability, such as the Q1 2026 loss, matters a lot for how investors interpret that model.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Hims & Hers Health on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With both risks and rewards in play, are you comfortable just following the crowd, or do you want to stress test the story yourself and move early by checking the 2 key rewards and 1 important warning sign?

See What Else Is Out There

Hims & Hers has returned to a quarterly loss and shows fragile profitability, which leaves investors questioning how reliable its earnings and margins really are.

If you want stocks where earnings look steadier and balance sheets can better absorb bumps like this, start comparing companies in the 69 resilient stocks with low risk scores today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.